After Stifel Nicolaus and Raymond James gave Galmed Pharmaceuticals (NASDAQ: GLMD) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Elemer Piros reiterated a Buy rating on Galmed Pharmaceuticals yesterday and set a price target of $59. The company’s shares closed yesterday at $13.11.
According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -8.3% and a 39.1% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Galmed Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $38, representing a 189.9% upside. In a report issued on August 2, Maxim Group also maintained a Buy rating on the stock with a $27 price target.
.
See today’s analyst top recommended stocks >>
Based on Galmed Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.69 million. In comparison, last year the company had a GAAP net loss of $2.69 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders.
Read More on GLMD:
